Sutro Biopharma, Inc. (STRO) came out with a quarterly loss of $0.91 per share versus the Zacks Consensus Estimate of a loss of $0.63. This compares to loss of $0.95 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -44.44%. A quarter ago, it was expected that this company would post a loss of $0.86 per share when it actually produced a loss of $0.89, delivering a surprise of -3.49%.Over the last four quarters, the company has s ...

Company Performance - Zymeworks Inc. reported a quarterly loss of $0.30 per share, better than the Zacks Consensus Estimate of a loss of $0.45, and an improvement from a loss of $0.42 per share a year ago, resulting in an earnings surprise of 33.33% [1] - The company posted revenues of $27.11 million for the quarter ended March 2025, exceeding the Zacks Consensus Estimate by 57.36%, compared to revenues of $10.03 million in the same quarter last year [2] - Over the last four quarters, Zymeworks has surpassed consensus EPS estimates four times, but has only topped consensus revenue estimates once [2] Stock Outlook - Zymeworks shares have declined approximately 22.5% since the beginning of the year, while the S&P 500 has decreased by 4.3% [3] - The company's earnings outlook will be crucial for future stock performance, with current consensus EPS estimates at -$0.51 for the coming quarter and -$1.75 for the current fiscal year [4][7] Industry Context - The Medical - Biomedical and Genetics industry, to which Zymeworks belongs, is currently ranked in the top 33% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact Zymeworks' stock performance [5]

Cantaloupe (CTLP) came out with quarterly earnings of $0.08 per share, missing the Zacks Consensus Estimate of $0.10 per share. This compares to earnings of $0.06 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -20%. A quarter ago, it was expected that this electronic payment and wireless networking company would post earnings of $0.06 per share when it actually produced earnings of $0.07, delivering a surprise of 16.67%.Over ...

Sight Sciences, Inc. (SGHT) came out with a quarterly loss of $0.28 per share versus the Zacks Consensus Estimate of a loss of $0.29. This compares to loss of $0.33 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 3.45%. A quarter ago, it was expected that this company would post a loss of $0.20 per share when it actually produced a loss of $0.23, delivering a surprise of -15%.Over the last four quarters, the company has surpas ...

Serve Robotics Inc. (SERV) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.21. This compares to loss of $0.37 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 23.81%. A quarter ago, it was expected that this company would post a loss of $0.19 per share when it actually produced a loss of $0.23, delivering a surprise of -21.05%.Over the last four quarters, the company has sur ...

Company Performance - Onto Innovation (ONTO) reported quarterly earnings of $1.51 per share, exceeding the Zacks Consensus Estimate of $1.47 per share, and up from $1.18 per share a year ago, representing an earnings surprise of 2.72% [1] - The company posted revenues of $266.61 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 0.62%, and an increase from $228.85 million year-over-year [2] - Onto Innovation has consistently surpassed consensus EPS and revenue estimates over the last four quarters [2] Stock Outlook - The stock has underperformed, losing about 24.9% since the beginning of the year, compared to the S&P 500's decline of 4.3% [3] - The current consensus EPS estimate for the upcoming quarter is $1.48 on revenues of $264.6 million, and for the current fiscal year, it is $6.09 on revenues of $1.07 billion [7] Industry Context - The Nanotechnology industry, to which Onto Innovation belongs, is currently ranked in the bottom 6% of over 250 Zacks industries, indicating potential challenges ahead [8] - The performance of Onto Innovation's stock may be influenced by the overall outlook for the industry, as research shows that the top 50% of Zacks-ranked industries outperform the bottom 50% by more than 2 to 1 [8]

Dropbox (DBX) came out with quarterly earnings of $0.70 per share, beating the Zacks Consensus Estimate of $0.62 per share. This compares to earnings of $0.58 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 12.90%. A quarter ago, it was expected that this online file-sharing company would post earnings of $0.62 per share when it actually produced earnings of $0.73, delivering a surprise of 17.74%.Over the last four quarters, t ...

Cardiff Oncology (CRDF) came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to loss of $0.22 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -5.26%. A quarter ago, it was expected that this molecular diagnostic company would post a loss of $0.25 per share when it actually produced a loss of $0.21, delivering a surprise of 16%.Over the last four quarters, the c ...

Company Performance - BioLife Solutions, Inc. reported quarterly earnings of $0.04 per share, exceeding the Zacks Consensus Estimate of a loss of $0.03 per share, and showing improvement from a loss of $0.19 per share a year ago, resulting in an earnings surprise of 233.33% [1] - The company achieved revenues of $23.94 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 5.28%, although this represents a decline from year-ago revenues of $31.73 million [2] - Over the last four quarters, BioLife Solutions has consistently surpassed consensus EPS estimates [2] Stock Performance - BioLife Solutions shares have declined approximately 17.8% since the beginning of the year, in contrast to the S&P 500's decline of 4.3% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.03 on revenues of $23.29 million, and for the current fiscal year, it is -$0.09 on revenues of $97.18 million [7] Industry Outlook - The Medical - Products industry, to which BioLife Solutions belongs, is currently ranked in the bottom 32% of over 250 Zacks industries, indicating potential challenges ahead [8] - The performance of BioLife Solutions may be influenced by the overall outlook of the industry, as historical data shows that the top 50% of Zacks-ranked industries outperform the bottom 50% by more than 2 to 1 [8]

Group 1 - Expedia reported quarterly earnings of $0.40 per share, missing the Zacks Consensus Estimate of $0.42 per share, but showing an increase from $0.21 per share a year ago, resulting in an earnings surprise of -4.76% [1] - The company posted revenues of $2.99 billion for the quarter ended March 2025, missing the Zacks Consensus Estimate by 1.27%, compared to $2.89 billion in the same quarter last year [2] - Over the last four quarters, Expedia has surpassed consensus EPS estimates three times and topped consensus revenue estimates two times [2] Group 2 - The stock has underperformed, losing about 10.6% since the beginning of the year, while the S&P 500 declined by -4.3% [3] - The current consensus EPS estimate for the coming quarter is $4.05 on revenues of $3.74 billion, and for the current fiscal year, it is $14.31 on revenues of $14.33 billion [7] - The Zacks Industry Rank indicates that the Internet - Commerce sector is currently in the top 30% of over 250 Zacks industries, suggesting a favorable outlook for the industry [8]